1. Market Research
  2. > Pharmaceutical Market Trends
  3. > GeneScience Pharmaceuticals Co., Ltd. - Product Pipeline Review - 2015

GeneScience Pharmaceuticals Co., Ltd. - Product Pipeline Review - 2015

  • October 2015
  • -
  • Global Markets Direct
  • -
  • 25 pages

GeneScience Pharmaceuticals Co., Ltd. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘GeneScience Pharmaceuticals Co., Ltd. - Product Pipeline Review - 2015’, provides an overview of the GeneScience Pharmaceuticals Co., Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of GeneScience Pharmaceuticals Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of GeneScience Pharmaceuticals Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of GeneScience Pharmaceuticals Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the GeneScience Pharmaceuticals Co., Ltd.’s pipeline products

Reasons to buy

- Evaluate GeneScience Pharmaceuticals Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of GeneScience Pharmaceuticals Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the GeneScience Pharmaceuticals Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of GeneScience Pharmaceuticals Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of GeneScience Pharmaceuticals Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of GeneScience Pharmaceuticals Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

GeneScience Pharmaceuticals Co., Ltd. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
GeneScience Pharmaceuticals Co., Ltd. Snapshot 5
GeneScience Pharmaceuticals Co., Ltd. Overview 5
Key Information 5
Key Facts 5
GeneScience Pharmaceuticals Co., Ltd. - Research and Development Overview 6
Key Therapeutic Areas 6
GeneScience Pharmaceuticals Co., Ltd. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
GeneScience Pharmaceuticals Co., Ltd. - Pipeline Products Glance 10
GeneScience Pharmaceuticals Co., Ltd. - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
GeneScience Pharmaceuticals Co., Ltd. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
GeneScience Pharmaceuticals Co., Ltd. - Unknown Stage Pipeline Products 12
Unknown Products/Combination Treatment Modalities 12
GeneScience Pharmaceuticals Co., Ltd. - Drug Profiles 13
Pegylated somatropin 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Gensci-006 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Gensci-007 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Gensci-008 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Gensci-003 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Gensci-028 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
GeneScience Pharmaceuticals Co., Ltd. - Pipeline Analysis 19
GeneScience Pharmaceuticals Co., Ltd. - Pipeline Products by Target 19
GeneScience Pharmaceuticals Co., Ltd. - Pipeline Products by Molecule Type 20
GeneScience Pharmaceuticals Co., Ltd. - Pipeline Products by Mechanism of Action 21
GeneScience Pharmaceuticals Co., Ltd. - Dormant Projects 22
GeneScience Pharmaceuticals Co., Ltd. - Locations And Subsidiaries 23
Head Office 23
Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 24
Disclaimer 25

List of Tables
GeneScience Pharmaceuticals Co., Ltd., Key Information 5
GeneScience Pharmaceuticals Co., Ltd., Key Facts 5
GeneScience Pharmaceuticals Co., Ltd. - Pipeline by Indication, 2015 7
GeneScience Pharmaceuticals Co., Ltd. - Pipeline by Stage of Development, 2015 8
GeneScience Pharmaceuticals Co., Ltd. - Monotherapy Products in Pipeline, 2015 9
GeneScience Pharmaceuticals Co., Ltd. - Phase II, 2015 10
GeneScience Pharmaceuticals Co., Ltd. - Preclinical, 2015 11
GeneScience Pharmaceuticals Co., Ltd. - Unknown, 2015 12
GeneScience Pharmaceuticals Co., Ltd. - Pipeline by Target, 2015 19
GeneScience Pharmaceuticals Co., Ltd. - Pipeline by Molecule Type, 2015 20
GeneScience Pharmaceuticals Co., Ltd. - Pipeline Products by Mechanism of Action, 2015 21
GeneScience Pharmaceuticals Co., Ltd. - Dormant Developmental Projects,2015 22

List of Figures
GeneScience Pharmaceuticals Co., Ltd. - Pipeline by Top 10 Indication, 2015 7
GeneScience Pharmaceuticals Co., Ltd. - Pipeline by Stage of Development, 2015 8
GeneScience Pharmaceuticals Co., Ltd. - Monotherapy Products in Pipeline, 2015 9
GeneScience Pharmaceuticals Co., Ltd. - Pipeline by Top 10 Target, 2015 19
GeneScience Pharmaceuticals Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015 20
GeneScience Pharmaceuticals Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.